Omeros (NASDAQ:OMER) Rating Lowered to Sell at StockNews.com

Omeros (NASDAQ:OMER) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

A number of other brokerages also recently issued reports on OMER. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Thursday, February 20th. Rodman & Renshaw initiated coverage on Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Down 10.6 %

OMER opened at $7.47 on Wednesday. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60. The business has a 50 day moving average price of $9.12 and a two-hundred day moving average price of $7.00. The company has a market cap of $432.89 million, a PE ratio of -3.23 and a beta of 2.03.

Institutional Trading of Omeros

Large investors have recently bought and sold shares of the company. Truvestments Capital LLC boosted its position in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 1,972 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Omeros in the fourth quarter valued at about $46,000. Picton Mahoney Asset Management grew its position in shares of Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 4,404 shares during the last quarter. Finally, US Bancorp DE purchased a new position in shares of Omeros during the 4th quarter worth approximately $81,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.